Table 4.
Demographic and baseline characteristics, treatment, and clinical outcomes of specific subgroups of kidney transplant recipients with COVID-19 infection.
| Characteristics of Patients with KTx for ≤1 year | |
|---|---|
| Age (years, mean ± SD) (n = 29) | 53.9 ± 13.9 |
| Gender (male) | 18/34 (53%) |
| Baseline sCr (mg/dL, median) (n = 21) | 1.24 (0.75–2.7) |
| Induction immunosuppression (n = 17) | |
| Antithymocyte globulin (ATG) | 8/17 (47%) |
| Basiliximab | 1/17 (6%) |
| Baseline Immunosuppression (n = 34) | |
| MPA + CNI ± CS | 31/34 (91.2%) |
| IS discontinuation | 9/34 (27%) |
| IS reduction | 18/34 (53%) |
| Antimetabolite withdrawal | 26/34 (77%) |
| COVID-19 Treatment | |
| Antivirals | 7/34 (21%) |
| HCQ | 18/32 (56%) |
| Azithromycin | 3/32 (9%) |
| Corticosteroids (IV) | 3/32 (9%) |
| Tocilizumab | 3/32 (9%) |
| Hospital admission | 32/34 (94%) |
| Admission to ICU | 9/32 (28%) |
| ARDS | 10/32 (31%) |
| AKI | 12/32 (38%) |
| Death | 5/34 (15%) |
| Characteristics of patients ≥ 65 years | |
| Age (years, mean ± SD) (n = 54) | 71.6 ± 4.7 |
| Gender (male) | 45/70 (64%) |
| Baseline sCr (mg/dL, median) (n = 23) | 1.8 (0.62–3.39) |
| Baseline Immunosuppression (n = 52) | |
| MPA/AZA + CNI ± CS | 34/52 (65%) |
| mTORi-based regimen | 9/52 (17%) |
| IS discontinuation | 28/54 (52%) |
| IS reduction | 17/54 (32%) |
| COVID-19 Treatment | |
| Antivirals | 19/69 (28%) |
| HCQ | 53/70 (76%) |
| Azithromycin | 19/63 (30%) |
| Corticosteroids (IV) | 18/70 (26%) |
| Tocilizumab | 11/70 (16%) |
| Hospital admission | 69/70 (99%) |
| Admission to ICU | 13/69 (19%) |
| ARDS | 32/69 (46%) |
| AKI | 24/68 (35%) |
| Death | 22/69 (32%) |
| Characteristics of patients who died | |
| Age (years, mean ± SD) (n = 37) | 64.2 ± 9.1 |
| Gender (male) | 37/61 (61%) |
| Baseline sCr (mg/dL, mean ± SD) (n = 20) | 2.14 ± 0.9 |
| IS discontinuation | 36/65 (55%) |
| IS reduction | 18/51 (35%) |
| COVID-19 Treatment | |
| Antivirals | 26/79 (33%) |
| HCQ | 51/64 (80%) |
| Azithromycin | 19/54 (35%) |
| Corticosteroids (IV) | 32/74 (43%) |
| Tocilizumab | 15/74 (20%) |
| Admission to ICU | 47/81 (58%) |
| ARDS | 62/77 (81%) |
| AKI | 26/45 (58%) |
Data are presented as the number/total number of available observations (percent) unless otherwise stated. Abbreviations: ATG: antithymocyte globulin.